BRAF and Miyoshi myopathy: In conclusion, this series of 177 BRAF-mutant MM patients treated with combined BRAFi/MEKi provides several important indications regarding the impact of DDIs on the toxicity profile of the treatment, offering insight into drug interactions in a real-world population.